Home > Insider Trading > Filing (0001225208-17-013087)

Filing Details

Accession Number:: 0001225208-17-013087
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-08-01 17:38:34
Reporting Period:: 2017-07-28

Filing Date:: 2017-08-01
Accepted Time:: 2017-08-01 17:38:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1099800	Edwards Lifesciences Corp	EW	Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)	364316614

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1196661	Jr E Donald Bobo	One Edwards Way Irvine CA 92614	Cvp, Heart Valve Therapy	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-07-28	5,300	$44.62	90,539	No	4	M	Direct
Common Stock	Disposition	2017-07-28	300	$115.86	90,239	No	4	S	Direct
Common Stock	Disposition	2017-07-28	2,500	$115.05	87,739	No	4	S	Direct
Common Stock	Disposition	2017-07-28	2,500	$114.16	85,239	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Acquire)	Disposition	2017-07-28	5,300	$0.00	5,300	$44.62

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
42,400	2012-05-12	2018-05-11	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	12,461	Indirect	401(k)
Common Stock	9,604	Indirect	By Trust

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017.
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator.
This transaction was executed in multiple trades at prices ranging from $115.69 to $115.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $114.63 to $115.5950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $113.58 to $114.51. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Shares represented on the most recent statement of Issuer's 401(k) Plan Administrator where a unitized accounting procedure is utilized to convert the equity to share equivalents.